Biotricity reports Q1 FY2023 revenue $2.1M, net loss $5M, launches Biotres and Bioheart

BIOTRICITY INC.

2024-Q1 EPS reported -$0.10 revenue$2,056,052

Revenue $2.1M; gross margin 60% consistent with FY22; net loss $5M ($0.098/sh); adjusted loss $0.085/sh.
Launched Biotres wireless holter patch after FDA clearance; also launched Biokit and Bioheart.
Expanded physician network to 29 states with over 2,000 physicians using products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.